What is HC Wainwright's Estimate for CervoMed Q3 Earnings?

Key Points

• HC Wainwright estimates that CervoMed will report a Q3 2025 earnings per share of ($0.66) and maintains a "Neutral" rating with a price target of $11.00.
• The consensus estimate for CervoMed's full-year earnings is projected at ($1.88) per share, with sequential estimates indicating continued losses into subsequent quarters.
• CervoMed stock currently has an average rating of "Moderate Buy" across analysts, with a consensus price target of $19.29.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of CervoMed in a research report issued on Monday, September 8th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.66) for the quarter. HC Wainwright currently has a "Neutral" rating and a $11.00 target price on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed's Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.60) EPS, Q1 2026 earnings at ($0.73) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.59) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.53) EPS.

CRVO has been the subject of a number of other research reports. Canaccord Genuity Group raised their target price on CervoMed from $21.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Chardan Capital restated a "buy" rating and issued a $15.00 target price on shares of CervoMed in a research note on Monday, August 11th. D. Boral Capital raised their target price on CervoMed from $15.00 to $31.00 and gave the company a "buy" rating in a research note on Monday, August 18th. Finally, Roth Capital restated a "buy" rating and issued a $16.00 target price (down previously from $20.00) on shares of CervoMed in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $19.29.

CervoMed Stock Down 4.8%

CRVO opened at $9.52 on Thursday. The stock has a market cap of $88.06 million, a PE ratio of -3.65 and a beta of -0.72. The business has a 50 day moving average of $8.76 and a 200-day moving average of $8.09. CervoMed has a 52 week low of $1.80 and a 52 week high of $20.63.

CervoMed (NASDAQ:CRVO - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.13). The business had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.45 million. CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Thompson Davis & CO. Inc. purchased a new position in CervoMed during the second quarter valued at $88,000. Jane Street Group LLC purchased a new position in CervoMed during the second quarter valued at $414,000. Marshall Wace LLP purchased a new position in CervoMed during the second quarter valued at $76,000. Rhumbline Advisers raised its stake in CervoMed by 35.5% during the first quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock valued at $53,000 after buying an additional 1,526 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of CervoMed in the 1st quarter worth $227,000. Hedge funds and other institutional investors own 25.15% of the company's stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.